Meet Cybrexa’s leadership team built on deep experience in oncology drug development, clinical trials, and company growth. Together, we are developing the next generation of cancer therapeutics and advancing the future of cancer treatment. bit.ly/4hbRVUm
Cybrexa Therapeutics Inc
@Cybrexa
Changing the paradigm for cancer treatment through the development of antigen-independent peptide drug conjugates.
CGs:bit.ly/3GI6AU0
CGs:bit.ly/3GI6AU0
141 Following 200 Followers 385 Posts
Latest posts 5
Cybrexa’s alphalex™- enabled peptide-drug conjugates bypass traditional therapy limits by targeting universal tumor biology. Our antigen-agnostic approach means more patients with cancer may benefit from treatment, regardless of specific tumor markers. bit.ly/3CobYzO
Cybrexa Therapeutics presented new preclinical data at #ESMOTAT25 showing alphalex™ peptide-drug conjugates achieved robust efficacy across multiple tumor models, both as monotherapy and in combination with standard treatments. Read the full results here: bit.ly/3FgoSkf
Cybrexa will present new preclinical findings at #ESMOTAT25 on the potential of alphalex™ peptide-drug conjugates to achieve tumor-selective delivery while minimizing off-target effects.
📅 March 3 | ⏰ 5:15-6:15 PM CET | 🎤 Vishwas Paralkar, Ph.D.
bit.ly/41uXCHv
📅 March 3 | ⏰ 5:15-6:15 PM CET | 🎤 Vishwas Paralkar, Ph.D.
bit.ly/41uXCHv
In a robust Phase 1 trial, our lead clinical-stage program, CBX-12, showed compelling safety & efficacy across six tumor types. With activity confirmed, even in heavily pretreated patients, we are advancing CBX-12 into Phase 2 trials. bit.ly/4ggu58J
#biotech
#biotech